All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What is the latest update on the GRAVITAS-309 trial?

Dec 14, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic GvHD.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Robert Zeiser, University of Freiburg, Freiburg, DE. We asked, What is the latest update on the GRAVITAS-309 trial?

What is the latest update on the GRAVITAS-309 trial?

In this interview, Zeiser presents the initial results from ASH abstract #771: ‘Itacitinib and Corticosteroids As initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravtias-309.’

Firstly, Zeiser discusses how the anti-inflammatory properties of itacitinib as a JAK 1 inhibitor may be beneficial in chronic GvHD. He goes on to outline the overall efficacy and safety of itacitinib in combination with corticosteroids.